Abstract
Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and “non-antimicrobial” pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field.
Keywords: Corticosteroids, efflux pump inhibitors, microenvironment, inflammation, TNF-α.
Current Molecular Medicine
Title:Novel Adjunctive Therapies for the Treatment of Tuberculosis
Volume: 14 Issue: 3
Author(s): A.A. Ordonez, M. Maiga, S. Gupta, E.A. Weinstein, W.R. Bishai and S.K. Jain
Affiliation:
Keywords: Corticosteroids, efflux pump inhibitors, microenvironment, inflammation, TNF-α.
Abstract: Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and “non-antimicrobial” pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field.
Export Options
About this article
Cite this article as:
Ordonez A.A., Maiga M., Gupta S., Weinstein E.A., Bishai W.R. and Jain S.K., Novel Adjunctive Therapies for the Treatment of Tuberculosis, Current Molecular Medicine 2014; 14 (3) . https://dx.doi.org/10.2174/1566524013666131118112431
DOI https://dx.doi.org/10.2174/1566524013666131118112431 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Control by Substrate of the Cytochrome P450-Dependent Redox Machinery: Mechanistic Insights
Current Drug Metabolism Graphical Abstracts:
Letters in Drug Design & Discovery Review: Studies on the Synthesis of Quinolone Derivatives with Their Antibacterial Activity (Part 1)
Current Organic Chemistry Demographic, Clinical and Laboratory Profiles of HIV Infected Patients Admitted into Imam Khomeini Hospital of Tehran, Iran
Infectious Disorders - Drug Targets Synthesis and Anti-Mycobacterial Activity of N-[(E)-(Disubstituted- Phenyl)Methylidene]Isonicotino-Hydrazide Derivatives
Letters in Drug Design & Discovery Novel Applications of Recombinant Lactic Acid Bacteria in Therapy and in Metabolic Engineering
Recent Patents on Biotechnology Platelets as Potential Immunomodulators: Is There a Role for Platelet Toll-Like Receptors?
Current Immunology Reviews (Discontinued) Ethnic Differences in Pharmacogenetically Relevant Genes
Current Drug Targets [1, 2, 4]-Oxadiazoles: Synthesis and Biological Applications
Mini-Reviews in Medicinal Chemistry Contemporary Overview on Clinical Trials and Future Prospects of Hepato-protective Herbal Medicines
Reviews on Recent Clinical Trials The Role of Macrophages in Rheumatoid Arthritis
Current Pharmaceutical Design Nebulizable Cycloserine Loaded PLGA Nanoparticles: Formulation Design, in vitro Evaluation and Stability Studies
Current Nanomedicine Coumarin Derivatives as Adjuvants: From In Silico Physicochemical Characterization to In Vitro Evaluation against Gram Positive Bacteria
Combinatorial Chemistry & High Throughput Screening Biological Evaluation of Halogenated Thioureas as Cholinesterases Inhibitors Against Alzheimer’s Disease & Molecular Modeling Studies
Letters in Drug Design & Discovery Current Trends and Future Directions of Fluoroquinolones
Current Medicinal Chemistry Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future
Current Pharmaceutical Design HIV and Respiratory Disease: A Contemporary Perspective
Current Respiratory Medicine Reviews Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Visceral Leishmaniasis: Advances in Treatment
Recent Patents on Anti-Infective Drug Discovery Experimental and Clinical Studies on Rifacinna® - The New Effective Antituberculous Drug (Review)
Recent Patents on Anti-Infective Drug Discovery